Cinthia Dinis da Costa, Sergio Duarte Dortas, Omar Lupi
{"title":"巴西特应性皮炎患者既往接受甲氨蝶呤和环孢素的杜匹单抗治疗。","authors":"Cinthia Dinis da Costa, Sergio Duarte Dortas, Omar Lupi","doi":"10.15586/aei.v53i4.1311","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Atopic Dermatitis (AD) is a chronic inflammatory skin disease that significantly impacts patients´ quality of life. Dupilumab was Brazil´s first biologic approved to treat moderate-to-severe AD. We aimed to assess the effectiveness and safety of dupilumab in a real-life setting for 16 weeks.</p><p><strong>Methods: </strong>Fourteen patients were evaluated at weeks 0, 4, and 16 after the first dupilumab shot. At each visit, disease activity and severity, itching intensity, and impact on quality of life were measured using the EASI (Eczema Area and Severity Index), IGA (Investigator's Global Assessment), SCORAD (Scoring Atopic Dermatitis), NRS (Numeric Rating Scale for itching), and DLQI (Dermatology Life Quality Index).</p><p><strong>Results: </strong>Clinical improvement observed was significant, with variation in all scores used in the study sample during the first 16 weeks of treatment (p < 0.0001).</p><p><strong>Conclusion: </strong>Dupilumab was effective and safe in our patients with moderate-to-severe AD.</p>","PeriodicalId":7536,"journal":{"name":"Allergologia et immunopathologia","volume":"53 4","pages":"149-152"},"PeriodicalIF":2.1000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A real-world study in Brazilian patients with atopic dermatitis treated with dupilumab who previously received methotrexate and cyclosporine.\",\"authors\":\"Cinthia Dinis da Costa, Sergio Duarte Dortas, Omar Lupi\",\"doi\":\"10.15586/aei.v53i4.1311\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Atopic Dermatitis (AD) is a chronic inflammatory skin disease that significantly impacts patients´ quality of life. Dupilumab was Brazil´s first biologic approved to treat moderate-to-severe AD. We aimed to assess the effectiveness and safety of dupilumab in a real-life setting for 16 weeks.</p><p><strong>Methods: </strong>Fourteen patients were evaluated at weeks 0, 4, and 16 after the first dupilumab shot. At each visit, disease activity and severity, itching intensity, and impact on quality of life were measured using the EASI (Eczema Area and Severity Index), IGA (Investigator's Global Assessment), SCORAD (Scoring Atopic Dermatitis), NRS (Numeric Rating Scale for itching), and DLQI (Dermatology Life Quality Index).</p><p><strong>Results: </strong>Clinical improvement observed was significant, with variation in all scores used in the study sample during the first 16 weeks of treatment (p < 0.0001).</p><p><strong>Conclusion: </strong>Dupilumab was effective and safe in our patients with moderate-to-severe AD.</p>\",\"PeriodicalId\":7536,\"journal\":{\"name\":\"Allergologia et immunopathologia\",\"volume\":\"53 4\",\"pages\":\"149-152\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2025-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Allergologia et immunopathologia\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.15586/aei.v53i4.1311\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"ALLERGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Allergologia et immunopathologia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.15586/aei.v53i4.1311","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ALLERGY","Score":null,"Total":0}
A real-world study in Brazilian patients with atopic dermatitis treated with dupilumab who previously received methotrexate and cyclosporine.
Introduction: Atopic Dermatitis (AD) is a chronic inflammatory skin disease that significantly impacts patients´ quality of life. Dupilumab was Brazil´s first biologic approved to treat moderate-to-severe AD. We aimed to assess the effectiveness and safety of dupilumab in a real-life setting for 16 weeks.
Methods: Fourteen patients were evaluated at weeks 0, 4, and 16 after the first dupilumab shot. At each visit, disease activity and severity, itching intensity, and impact on quality of life were measured using the EASI (Eczema Area and Severity Index), IGA (Investigator's Global Assessment), SCORAD (Scoring Atopic Dermatitis), NRS (Numeric Rating Scale for itching), and DLQI (Dermatology Life Quality Index).
Results: Clinical improvement observed was significant, with variation in all scores used in the study sample during the first 16 weeks of treatment (p < 0.0001).
Conclusion: Dupilumab was effective and safe in our patients with moderate-to-severe AD.
期刊介绍：
Founded in 1972 by Professor A. Oehling, Allergologia et Immunopathologia is a forum for those working in the field of pediatric asthma, allergy and immunology. Manuscripts related to clinical, epidemiological and experimental allergy and immunopathology related to childhood will be considered for publication. Allergologia et Immunopathologia is the official journal of the Spanish Society of Pediatric Allergy and Clinical Immunology (SEICAP) and also of the Latin American Society of Immunodeficiencies (LASID). It has and independent international Editorial Committee which submits received papers for peer-reviewing by international experts. The journal accepts original and review articles from all over the world, together with consensus statements from the aforementioned societies. Occasionally, the opinion of an expert on a burning topic is published in the "Point of View" section. Letters to the Editor on previously published papers are welcomed. Allergologia et Immunopathologia publishes 6 issues per year and is included in the major databases such as Pubmed, Scopus, Web of Knowledge, etc.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
